financetom
Business
financetom
/
Business
/
Market Chatter: Goldman Sachs Hires Former Citigroup Banker Matt Beitzel to Lead Dealmaking in Financial Institutions Group
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Goldman Sachs Hires Former Citigroup Banker Matt Beitzel to Lead Dealmaking in Financial Institutions Group
Aug 20, 2024 12:11 PM

02:56 PM EDT, 08/20/2024 (MT Newswires) -- Goldman Sachs Group ( GS ) has hired former Citigroup (C) banker Matt Beitzel as a partner in its financial institutions group to oversee dealmaking initiatives with banks and financial firms in the Americas, Reuters reported Monday, citing a company memo.

Beitzel, who previously led Citigroup's ( C ) North American banks, will start at Goldman in November, people familiar with the matter reportedly told Reuters.

A spokesperson for Goldman confirmed the memo's content, Reuters reported.

Goldman Sachs ( GS ) and Citigroup did not immediately respond to MT Newswires' requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 499.21, Change: -5.47, Percent Change: -1.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies
Champions Oncology Says It Has Obtained License to Use Radioactive Materials in Preclinical Studies
May 25, 2025
11:27 AM EDT, 04/28/2025 (MT Newswires) -- Champions Oncology ( CSBR ) said Monday it has obtained a license to use radioactive materials in preclinical studies, expanding its ability to develop and test targeted radiotherapies in-house. The license allows Champions to integrate radionuclide-based therapeutic testing with its patient-derived xenograft models platform, supporting drug developers across modalities like antibody-radionuclide conjugates and...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Why Cantor Equity Partners (CEP) Stock Is Up 200% Over The Past Week
Why Cantor Equity Partners (CEP) Stock Is Up 200% Over The Past Week
May 25, 2025
Shares of Cantor Equity Partners Inc ( CEP ) have soared 202% to $32.76 over the past week, fueled by news of a merger with newly formed Bitcoin-focused firm Twenty One. What To Know: The combined company, valued at $3.6 billion, is set to become the third-largest public holder of Bitcoin (CRYPTO: BTC), behind only Strategy and Tether. Twenty One...
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical
May 25, 2025
11:24 AM EDT, 04/28/2025 (MT Newswires) -- Oramed Pharmaceuticals ( ORMP ) said on Monday it has closed on a $36.9 million strategic investment in Alpha Tau Medical ( DRTS ) , acquiring 14.1 million of the clinical-stage oncology therapeutics company's shares at $2.61 apiece. Under terms of their collaboration agreement, Oramed will provide investor and shareholder outreach support to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved